Proficio Capital Partners LLC Buys New Shares in Ascendis Pharma A/S (NASDAQ:ASND)

Proficio Capital Partners LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 12,528 shares of the biotechnology company's stock, valued at approximately $1,725,000.

A number of other institutional investors have also modified their holdings of the stock. Legato Capital Management LLC raised its stake in shares of Ascendis Pharma A/S by 7.5% in the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock valued at $264,000 after purchasing an additional 134 shares in the last quarter. Jones Financial Companies Lllp grew its position in shares of Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock valued at $34,000 after buying an additional 197 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S during the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its position in shares of Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter. Finally, Thrivent Financial for Lutherans grew its position in shares of Ascendis Pharma A/S by 0.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company's stock valued at $11,717,000 after buying an additional 228 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ASND. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research report on Tuesday, March 18th. UBS Group began coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Morgan Stanley set a $180.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, Evercore ISI upped their target price on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the stock an "outperform" rating in a research report on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $204.64.

Remove Ads

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $2.75 during trading on Friday, reaching $165.99. The company had a trading volume of 354,250 shares, compared to its average volume of 459,253. The firm's fifty day moving average is $141.37 and its 200 day moving average is $135.69. The firm has a market capitalization of $10.07 billion, a PE ratio of -23.38 and a beta of 0.62. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) earnings per share for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.